Glasdegib
Glasdegib (pronunciation: glas-DEH-gib) is a pharmaceutical drug used in the treatment of acute myeloid leukemia (AML). It is marketed under the brand name Daurismo by Pfizer.
Etymology
The name Glasdegib is derived from the chemical structure of the drug. The prefix Glas- is an acronym for Gli1 Antagonist Small molecule, referring to the drug's mechanism of action as an inhibitor of the Hedgehog signaling pathway protein Gli1. The suffix -gib is a common ending for Hedgehog pathway inhibitors.
Pharmacology
Glasdegib is a small molecule inhibitor of the Hedgehog signaling pathway, specifically targeting the Smoothened (SMO) receptor. By inhibiting SMO, Glasdegib prevents the activation of the GLI family of transcription factors, thereby inhibiting the growth of cancer cells.
Clinical Use
Glasdegib is used in combination with low-dose cytarabine, a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia in adults who are 75 years or older or who have comorbidities that preclude intensive induction chemotherapy.
Side Effects
Common side effects of Glasdegib include fatigue, anemia, hemorrhage, febrile neutropenia, musculoskeletal pain, nausea, edema, thrombocytopenia, dyspnea, decreased appetite, dysgeusia, mucositis, constipation, and rash.
See Also
External links
- Medical encyclopedia article on Glasdegib
- Wikipedia's article - Glasdegib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski